The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Emerging management options for AML
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares his thoughts on the evolving therapeutic landscape of acute myeloid leukemia (AML) and what we are likely to see in the future. This includes the incorporation of novel agents, alone and in combination, into standard-of-care backbones, and replacing intensive chemotherapy for all patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
